Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Recruiting
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
First received: December 6, 2005
Last updated: August 8, 2011
Last verified: December 2010
Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis that endothelial function will be better in the BNP treated patients compared to the NTG treated patients

Condition Intervention Phase
Coronary Artery Disease
Drug: Nesiritide,
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1

Resource links provided by NLM:

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • FMD [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 500
Study Start Date: July 2005
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Nesiritide,

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:coronary artery disease -

Exclusion Criteria:CHF and/or reduced LV function, or renal failure with Creatinine >2mg%

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00262574

Contact: Yonathan Hasin, prof. 97246652649 yhasin@poria.health.gov.il
Contact: Diab gahnim, Dr

The Baruch Pade medical center, Poriya Recruiting
Tiberias, Israel, 15208
Principal Investigator: Yonathan Hasin, Profesor         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Principal Investigator: Mina Arinos Ministry of Health, Israel
  More Information

Responsible Party: prof yonathan hasin, Israell health ministry
ClinicalTrials.gov Identifier: NCT00262574     History of Changes
Other Study ID Numbers: 20020474-Hasin-BNP.CTIL 
Study First Received: December 6, 2005
Last Updated: August 8, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by The Baruch Padeh Medical Center, Poriya:
endothelial disfunction
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016